<DOC>
	<DOC>NCT00539786</DOC>
	<brief_summary>PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.</brief_summary>
	<brief_title>The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Patients with extraesophageal manifestation symptoms of GERD laryngeal, pharyngeal, liver, lung, renal, or hematological disorders a history of gastrointestinal surgery, and a history of connective tissue disorders. patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Patients with extraesophageal manifestation of gastroesophageal reflux disease</keyword>
</DOC>